Navigation Links
SGX Pharmaceuticals Submits Investigational New Drug Application for SGX393
Date:6/30/2008

able at a future date.

About SGX Pharmaceuticals

SGX Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development and commercialization of novel, targeted therapeutics directed at addressing unmet medical needs in oncology. The Company's drug development programs target the MET receptor tyrosine kinase, an enzyme implicated in a broad array of cancers, and the BCR-ABL tyrosine kinase enzyme for the treatment of CML. The Company's drug discovery activities are focused on a portfolio of other protein and enzyme targets that have been implicated in human cancers, including JAK2, RON, ALK, RAS and IKKe. More information on the pipeline and drug discovery platform can be found at http://www.sgxpharma.com and in the Company's various filings with the Securities and Exchange Commission.

Forward Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include, but are not limited to, the potential of SGX393 as a treatment for CML, and the ability of the company to discover, develop and commercialize cancer therapeutics. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug discovery, development and commercialization. The results of early preclinical studies or clinical trials may not be predictive of future results, and the Company cannot provide any assurances that any of its compounds or development candidates will have favorable results in preclinical studies or future clinical trials or that the FDA will approve the commencement of clinical trials. For a discussion of these and other factors, please refer to the risk factors descri
'/>"/>

SOURCE SGX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. VIA Pharmaceuticals Set to Join Russell Microcap Index
2. Wyeth Pharmaceuticals Announces Organizational Change
3. Access Pharmaceuticals Presents New Data at International Symposium Showing Companys Angiolix(R) Monoclonal Antibody has Potential to Treat Cancer by Attacking Cancer Stem Cells
4. Keryx Biopharmaceuticals to Present at the Jefferies & Co. Healthcare Conference
5. Portola Pharmaceuticals Names William Lis Vice President of Business Development and Commercial Operations
6. Stason Pharmaceuticals, Inc. Appoints Diana Wood as Vice President, Business Development
7. Brian Levy, OD, MSc, Named Chief Operating Officer of Danube Pharmaceuticals
8. Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008
9. Onyx Pharmaceuticals to Present at Jefferies 2nd Annual Healthcare Conference
10. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
11. Immtech Pharmaceuticals and Beijing Capital Medical University Announce Joint Venture to Provide Contract Research Services in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2009)... opening of a NEW 2nd North American facility in Marietta, OH. ... center to support Esco,s growth in the North American market, specifically ... equipment. , ... Hatboro, PA (PRWEB) December 11, 2009 ... facility in Marietta, OH. The facility will serve as a technical ...
(Date:12/10/2009)... the National Institutes of Health (NIH), awarded a $2.18 million ... a non-invasive, passive diffusion-based treatment for severe, non-infectious uveitis. ... ... UT (PRWEB) December 10, 2009 -- The National Eye Institute ... awarded a $2.18 million grant to Aciont Inc. to help ...
(Date:12/10/2009)... Instrument, a world-leading provider of advanced flow measurement, ... will join the company as Global Level Product ... Brooks Instrument’s efforts to enhance market penetration of ... is joining Brooks Instrument from Lafarge Corp, a ... Director of Marketing and Sales. Bayda will report ...
(Date:12/10/2009)... Biomatrica, the leader in room temperature ... SampleWare 3.1 software system for laboratory inventory, organization ... now includes an audit trail functionality that tracks ... complete history of any stored sample. ,, ... customers a much needed ability to track all ...
Breaking Biology Technology:NEI Awards a Two-Year $2.18 Million SBIR Grant to Aciont 2NEI Awards a Two-Year $2.18 Million SBIR Grant to Aciont 3Brooks Instrument Appoints Mike Bayda as Global Level Product Manager 2Brooks Instrument Appoints Mike Bayda as Global Level Product Manager 3Biomatrica Launches SampleWare 3.1 2Biomatrica Launches SampleWare 3.1 3
... its strategy of digital convergence on Thursday at the Consumer ... home entertainment service. , ,Designed as part of the ... satellite TV, digital video recording and Internet service in a ... and DSL connection. , ,In his keynote address, SBC chairman ...
... , Milwaukee Johnson Controls plans ... company that will pay approximately 330 million Euros, or $430 ... France. Johnson Controls bought it in 2001 from another French ... 350 million Euros. , SBC Foundation donates $1 million to ...
... an experimental CIMSS satellite. Courtesy of UW-Madison. ... as the weather, the University of Wisconsin's Cooperative ... computer. , ,The institute has begun testing its weather ... offered by Silicon Graphics Inc. , a company ...
Other Biology Technology:SBC blends TV, video, music and the Internet in a new media box 2UW-Madison picks scalable SGI computer to simulate weather 2UW-Madison picks scalable SGI computer to simulate weather 3
(Date:12/11/2009)... PAAs consumer demand for premium fruit increases, growers ... to market. And to boost their bottom line, ... can increase fruit quality while reducing labor costs. ... growers to produce larger, healthier fruit, is among ... significant impact on fruit production overhead, and, ultimately, ...
(Date:12/11/2009)... University has granted an 18-month, exclusive option to ... insulin analogs. The company must reach certain milestones ... an exclusive license on therapies designed to help ... developing treatments that it hopes will become an ... insulin market. Insulin is a therapeutic protein used ...
(Date:12/11/2009)... December 11, 2009 Keystone Symposia on Molecular ... appointment of five new Keystone Symposia Fellows for ... five talented early-career life scientists (postdoctoral trainees or ... development process for one year. Fellows are selected ... a commitment to promoting diversity in the biomedical ...
Breaking Biology News(10 mins):Horizontal string trimmer reduces labor costs, increases peach size 2Case Western Reserve University grants option to startup Thermalin Diabetes Inc. 2Keystone Symposia appoints 5 Fellows as part of diversity in life science initiative 2Keystone Symposia appoints 5 Fellows as part of diversity in life science initiative 3Keystone Symposia appoints 5 Fellows as part of diversity in life science initiative 4Census Bureau to Announce Findings for Income Earnings Poverty and Health Insurance Coverage 56596 1Census Bureau to Announce Findings for Income Earnings Poverty and Health Insurance Coverage 56596 2Survey Shows At Risk Men Lacking In Prostate Cancer Knowledge 56594 1Survey Shows At Risk Men Lacking In Prostate Cancer Knowledge 56594 2Survey Shows At Risk Men Lacking In Prostate Cancer Knowledge 56594 3Survey Shows At Risk Men Lacking In Prostate Cancer Knowledge 56594 4Survey Shows At Risk Men Lacking In Prostate Cancer Knowledge 56594 5Survey Shows At Risk Men Lacking In Prostate Cancer Knowledge 56594 6Survey Shows At Risk Men Lacking In Prostate Cancer Knowledge 56594 7Survey Shows At Risk Men Lacking In Prostate Cancer Knowledge 56594 8Survey Shows At Risk Men Lacking In Prostate Cancer Knowledge 56594 9PDL BioPharma to Present at BioCentury Newsmakers Conference on September 16 2009 56592 1
... one of two teams in an international effort to ... to understand the role of individual genes in human ... School of Veterinary Science at the University of California, ... England. The National Institutes of Health (NIH), announced ...
... clinical trial evaluating new drug combinations for sleeping sickness, ... Medecins Sans Frontieres (MSF), and its research arm, Epicentre, ... Trials. , African trypanosomiasis, or sleeping sickness affects many tens ... and is a serious disease for which there are ...
... of countries and regions are transitioning from deforestation to ... world as a whole, according to researchers advancing a ... novel approach looks beyond simply how much of a ... volume of timber, biomass, and captured carbon within the ...
Other Biology News:Knockout Mouse Project 2End of deforestation in view? Experts advance new way to size up global forest resources 2End of deforestation in view? Experts advance new way to size up global forest resources 3End of deforestation in view? Experts advance new way to size up global forest resources 4End of deforestation in view? Experts advance new way to size up global forest resources 5End of deforestation in view? Experts advance new way to size up global forest resources 6
... This reagent has been developed ... for the reduction of nonspecific background ... Traditional methods describe blocking peroxidase with ... hydrogen peroxide in combination with additional ...
Phospho-Btk (Tyr223) Antibody...
Rad51B...
p27 rabbit polyclonal antibody...
Biology Products: